Xentria Advances XTMAB-16 Clinical Development in Pulmonary Sarcoidosis Following FDA Feedback

Phase 2XTMAB-16Positive

AI Analysis

Summary

Xentria advanced XTMAB-16 clinical development in pulmonary sarcoidosis following FDA feedback, with Part A data supporting a proposed amendment to Part B of the XTMAB-16-201 trial to evaluate a 4mg/kg dose.

Clinical Trial Data

Phase

Phase 2

Outcome Details

XTMAB-16-201 Part A provided pharmacokinetic exposure, target-coverage, immunogenicity, safety and feasibility findings that informed next-stage development plan; Part B amendment proposed to evaluate 4mg/kg dose

Importance:5/10

Sentiment:

0.50

clinical developmentPhase 2pulmonary sarcoidosisFDA feedbackpharmacokinetics

Related Companies

$INBP $CBDY

Read the original article

Published by PR Newswire Biotech on September 1, 2026 11:00 AM

Read Original